palmitoylethanolamide.com.au
Menu
Home › Research › Marcella 2021

Phytotherapics in COVID19: Why palmitoylethanolamide?

Marcella Pesce, Luisa Seguella, Sara Cassarano, Laura Aurino, Walter Sanseverino, Jie Lu, Chiara Corpetti, Alessandro Del Re, Martina Vincenzi, Giovanni Sarnelli, Giuseppe Esposito. Phytother Res. 2021 May;35(5):2514-2522.

ReviewHumans

Design
Review
Subjects
Not stated in the abstract
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
Why palmitoylethanolamide might help with COVID-19: its history as a nutraceutical for infectious and respiratory disease, and how earlier evidence might apply

What the authors reported

No PEA-specific data on COVID-19 are reported. The authors trace PEA's history back to the 1970s, when it was sold as Impulsin for influenza, and report that FSD Pharma received FDA clearance to design a proof-of-concept study of ultramicronised PEA in COVID-19.

Limits of this study

A narrative review with no trial data on COVID-19 and no numbers. Funding and conflicts not stated in the abstract.

Source

PubMed 33296131 · doi:10.1002/ptr.6978

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.